IMA Stock — ImageneBio Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. Our lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (“OX40L”).

Source: 10-K FY2025 via SEC EDGAR

Share price

$4.14

Market cap

$47.0M

Cash

$136.2M

Enterprise value

-$89.2M

Balance sheet

Cash	$136.2M
Debt	$0.0M
Net cash	$136.2M
Enterprise value	-$89.2M
Basic shares	11.3M shares
Fully diluted shares	19.3M shares
Fully diluted market cap	$80.0M
Cash per share	$12.07
Quarterly burn	$9.1M
Cash runway	15.0 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

11.3M

Pre-funded warrants

5.8M

Options

1.4M

RSUs

0.7M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.2M

FDSO

19.3M

Cap table as of 2026-06-30.

Price history

Loading IMA daily closes…

Loading price history…

Next catalyst

olevaprubart (IMG-007) · Est. Nov 15, 2027 · quarter midpoint · guided in 11 mo

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2027 in 11 mo quarter midpoint	olevaprubart (IMG-007) ADAPTIVE Phase 2b topline (atopic dermatitis)	Phase 2b	Not disclosed	Q4 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Olevaprubart

Phase 2 · Active Modality: non-depleting monoclonal antibody

Aliases IMG-007

Target OX40 receptor

Indications

Atopic dermatitis (AD) (Phase 2)
Alopecia areata (AA) (Phase 2)

Status note Multi-country Phase 2b dose-finding AD study began 2025; protocol amendment submitted to FDA and Health Canada for optimized dose exposure. Phase 1b/2a POC in severe AA completed (29 patients).

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
BVF Partners	1,110,002	no change	0.17%	2026-08-14
OrbiMed Advisors	909,269	+530,713	0.10%	2026-08-14
RTW Investments	334,445	no change	0.02%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

IMA — ImageneBio Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

IMA — ImageneBio Inc.